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ABSTRACT 
Objective: The objective of this selective evidence based medicine (EBM) review is to 
determine whether or not ranibizumab improves best corrected visual acuity (BCVA) in adults 
with diabetic macular edema compared to patients who do not receive ranibizumab 
Study Design: The selective review examined best corrected visual acuity values reported from 
published, primary literature sources that examined the efficacy of ranibizumab in diabetic 
macular edema 
Data Sources: Two double blind randomized controlled trials and one case control study were 
selected and reviewed 
Outcomes Measured: Best corrected visual acuity (BCVA) as measured from Early Treatment 
Diabetic Retinopathy Study visual acuity charts, which were converted to dichotomous data to 
determine treatment effects. Adverse events were also considered in this selective review to 
determine safety of this therapeutic intervention. 
Results: Mean BCVA improvements were 10.3, 9, and 13 with all p-values < 0.05 compared to 
statistically significant decline in acuity in control arms. Adverse event rates were notably higher 
in therapeutic arms but only a minority was serious adverse events (SAE). 
Conclusion: All reported increases in BCVA suggests that indeed ranibizumab is an effective 
therapeutic option for diabetic macular edema but requires continued investigation to further 
elaborate its safety profile outside a controlled research setting 
 
Key Words: Ranibizumab, Lucentis, diabetic macular edema, diabetic retinopathy, macular 
edema, VEGF inhibitors 
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 Diabetic macular edema (DME) is a common manifestation of diabetic retinopathy, 
causing blurred vision due to the edema of the macula. In a diabetic patient, poorly controlled 
hyperglycemia triggers several cascades of pathologic mechanisms. One such pathway both 
induces the apoptosis of pericytes that surround retinal vessels as well as thickens the basement 
membrane of the very same vessels, which allows microaneurysms to occur and the leaking of 
plasma in the retinal layers to include the macula. Though the eye is capable of tolerating a 
certain volume of leaked fluid in the retina, hyperglycemia and retinal ischemia also trigger the 
release of vascular endothelial growth factor (VEGF). VEGF is a key signaling protein that 
promotes a pathologic angiogenesis; the body increases the vasculature in the retina, which is 
prone to the same microaneurysms and leaking. A combination of neovascularization and porous 
vessels leads to the rapid accumulation of plasma fluid, leading to diminishing visual acuity. 
Epidemiology 
 Diabetes mellitus and its complications have a regrettably high impact and prevalence in 
the United States; therefore physician assistants will undoubtedly encounter, diagnose, and treat 
this disease. In 2010, the CDC estimated that approximately 25.8 million individuals suffered 
from diabetes mellitus in the United States.1 Of these diabetics, nearly 100% of type 1 diabetics 
and approximately 60% of type 2 diabetics are projected to develop diabetic retinopathy over the 
course of 15 to 20 years.2 In light of its incidence, it is imperative for physician assistants and 
other healthcare providers to prepare themselves to be able to identify and treat this condition 
accurately and effectively. 
 Likewise, diabetic retinopathy has a significant impact on the patient and social welfare 
programs. In a study comparing Medicare reimbursements to diabetics without and with macular 
edema, the investigators found that Medicare paid an additional $2,892 per Medicare beneficiary 
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with diabetic macular edema within the first year of diagnosis.3 At three years following the 
diagnosis, Medicare reimbursed on average an additional $8,312 per Medicare beneficiary with 
diabetic macular edema.3 While the cost to the federal government is clear, it may also be 
surmised that the cost to the patient rises as well with co-pays, deductibles, and associated 
logistical costs (e.g. transportation). 
 Diabetic retinopathy also substantially affects the time spent by both provider and patient. 
In another study examining the impact of this manifestation of diabetic retinopathy, it was 
estimated that patients with diabetic macular edema have three times more ophthalmologic visits 
than those who do not, with approximately 3.9 visits per year.4 With an estimated prevalence of 
2 million suffering diabetic retinopathy in the United States2, this comes out to approximately 8 
million healthcare visits in the United States per year. 
Current & Future Therapies 
 With the impact of diabetic retinopathy & macular edema established, the logical 
questions to investigate are what is known about the disease and what can be done to combat it. 
As described earlier, much is already known about the etiology and pathophysiology of diabetic 
macular edema; however the elusive piece of the puzzle is curative therapy. 
 Current therapies focus on glycemic control and focal laser photocoagulation. Tight 
glycemic control in patients with diabetes mellitus is the most effective therapy, but this efficacy 
is lost as retinopathy progresses to advanced stages. This leaves focal laser coagulation as the 
mainstay of therapy for diabetic macular edema. Unfortunately this therapy is far from ideal; 
patients undergoing the procedure may expect a modest improvement in best corrected visual 
acuity (BCVA) by 30%, and up to 20% of those who receive laser photocoagulation will 
experience a worsening of their vision.1 
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 The risks and limited efficacy of focal laser photocoagulation has driven the search for a 
more effective therapy that can help restore visual acuity in patients with diabetic macular edema. 
Ranibizumab (trade name Lucentis) is a result of such research. Ranibizumab is a monoclonal 
antibody, which inhibits VEGF-A and thereby prevents the angiogenesis of excessive, weak 
vasculature that would otherwise leak plasma into the retinal layers & macula. It is among the 
first generation of promising treatments that may help restore vision in those with diabetic 
macular edema but is also relatively new and requires further examination. 
OBJECTIVE 
 Therefore the objective of this selective review is to determine whether or not 
ranibizumab improves BCVA in adults with diabetic macular edema. 
METHODS 
Criteria 
 To examine this question, this paper focuses on adults (age ! 18 years old) with a 
diagnosis of diabetic macular edema. Interventions that were considered in a literature search 
included intravitreal injections of ranibizumab, placebo injections, and focal laser 
photocoagulation, provided the study had at least one arm including ranibizumab as an 
intervention and one without. The quantifiable, objective outcome used was BCVA as assessed 
through the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart. Types 
of studies considered were randomized controlled trials; however one study that was selected and 
included in data analysis was a case control study.  
Data Sources 
 A search of English-language published, primary literature was performed through 
various, reputable search engines to include MedLine, PubMed, and Ovid. Key words used in the 
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search included: Lucentis, ranibizumab, diabetic macular edema, and diabetic retinopathy.  A 
Cochrane systematic review regarding the efficacy of ranibizumab on visual acuity in diabetics 
with macular edema was found dating 2009; therefore only articles published following this date 
were considered in this review as part of the inclusion criteria. Exclusion criteria included the 
effects of ranibizumab on other similar ophthalmologic pathologies and studies using subjective 
metrics to gauge the efficacy of this novel monoclonal antibody. 
 Ultimately, three studies were selected: a double-blind randomized controlled trial 
conducted by Massin et al in 2010 (i.e. the RESOLVE study)5, another double-blinded 
randomized controlled trial conducted by the Diabetic Retinopathy Clinical Research Network 
(DRCRN) in 20106, and a case control study led by Ozturk et al in 2011.7  
Massin et al published the findings of a multicenter, phase II clinical trial on ranibizumab 
on its safety and efficacy on study participants with diabetic macular edema. The study was 
designed as a double-blinded, randomized control trial. The investigators randomized subjects 
into three arms: 0.3 mg intravitreal injections, 0.5 mg intravitreal injections, and sham treatment 
as the control group; they then measured best corrected visual acuity in their subjects at various 
time points to include 12 months following treatment. The study was selected for its quality 
design and large sample size from different sites. 
The 2010 DRCRN study was a multicenter phase III clinical trial conducted as a double-
blinded, randomized controlled trial. The investigators compared the following interventions in 
the study: (1) sham intravitreal injection followed by prompt (within 3-10 days of injection) focal 
laser photocoagulation; (2) 0.5 mg ranibizumab injection followed by prompt focal laser 
photocoagulation; (3) 0.5 mg ranibizumab injection followed by deferred (! 24 weeks) focal 
laser photocoagulation; and (4) 4 mg triamcinolone injection followed by prompt focal laser 
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photocoagulation. Though this selective review seeks to compare treatment of ranibizumab in 
those suffering diabetic macular edema with those who do not receive it, it was decided that only 
the first two interventions listed were truly comparable to be able to better attribute therapeutic 
effect (if any) of ranibizumab compared to placebo. Follow up was performed both at 1 year and 
3 years following treatment. To ensure maximal consistency with the RESOLVE study, data 
points from the 1-year mark was examined in this review. This too was selected for its quality 
design and large sample size from different sites. 
Ozturk et al performed a case control study examining the clinical records of patients 
with diabetic macular edema who received either ranibizumab or bevacizumab (a similar VEGF 
inhibitor) and compared improvement in BCVA. The study encompassed 29 eyes of 29 patients, 
and these patients received either 0.5 mg ranibizumab intravitreal injection or a 1.25 mg 
bevacizumab intravitreal injection. Both Snellen charts and ETDRS visual acuity charts were 
used to assess improvements in patient’s vision. Due to the limited number of quality studies 
following 2009, this study was selected not only for its quality but its consistency in measuring 
outcomes following administration of ranibizumab. 
Both the RESOLVE study and the 2010 Diabetic Retinopathy Clinical Research Network 
study reported mean changes in BCVA with 95% confidence intervals and its associated p-
values. The RESOLVE study further reports relative risk values associated with the gain or loss 
of letters in BCVA. Ozturk et al reported mean & median changes as BCVA values with 
associated p-values. 
Information regarding the inclusion and exclusion criteria as well as specific 
interventions of the selected studies is summarized in Table 1.  
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OUTCOMES MEASURED 
 As previously stated, best-corrected visual acuity was measured in all three selected 
studies with the ETDRS visual acuity chart, an instrument that is similar to the Snellen chart and 
is used in clinical research assessing visual acuity. The chart, designed by Ferris et al in 19828, 
has become the gold standard in assessing visual acuity in clinical research studies9 and defines 
with greater resolution the subtle differences of visual acuity that cannot be captured by the 
Snellen chart. This metric, known as BCVA, uses the total number of letters that a research 
subject can read in order to gauge their visual deficit. It can be read from a variety of distances 
depending on the size of the chart itself. As previously stated, best corrected visual acuity 
(BCVA) was the outcome measured in each of the three selected studies. In the RESOLVE study, 
investigators assessed BCVA of study participants at baseline, 1 month, and 12 months post 
treatment. Similarly, the 2010 Diabetic Retinopathy Clinical Research Network study and Ozturk 
et al had participants do the same with the ETDRS visual acuity chart. 
RESULTS 
Efficacy 
 In the RESOLVE study, at 12 months, the mean BCVA was 10.3 ± 9.1 letters improved 
from the baseline in patients receiving ranibizumab injections versus the 1.4 ± 14.2 letter decline 
in the control group (p<0.0001). For analysis purposes, continuous data was converted to 
dichotomous data, and a minimum improvement of 10 letters or more was considered therapeutic 
improvement in vision. Again at 12 months, 60.8% of individuals receiving the investigated drug 
experienced this level of improvement compared to the 18.4% of the control group experiencing 
this improvement. These values demonstrate a clear efficacy of the investigational new drug in 
the improvement of best corrected visual acuity. 
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The authors of the DRCRN study also reported treatment effects as continuous data, 
which was converted to dichotomous data for this selective review. Mean change in BCVA in 
study participants receiving ranibizumab and prompt photocoagulation at 12 months was a gain 
in 9 ± 11 letters while those in the control arm experienced a gain of 3 ± 13. The difference in 
mean change was reported to be a range of +3.2 to +8.5 with intravitreal ranibizumab injections 
at a 95% CI (p < 0.001). When comparing efficacy of ranibizumab versus control in the two 
prompt photocoagulation arms, approximately 50.8% of diabetics receiving ranibizumab enjoyed 
a 10 letter or more increase in BCVA compared to the 27.6% among the control group. Though 
both arms received focal photocoagulation, the relative benefit increase (RBI) clarifies the 
proportional effect of ranibizumab at  an 84.1% increase. Additional figures on treatment effects 
follow in Table 2. 
Ozturk and his colleagues performed a case control study, providing less substantial but 
nonetheless meaningful data. The study found pretreatment mean score to be 52.29 ± 17.76 and 
posttreatment scores to be 60.52 ± 18.44, with a median improvement from 53 to 66 (p < 0.001). 
 
Safety  
As previously stated, the RESOLVE study also examined the safety profile of 
ranibizumab in study participants differentiating serious adverse events (SAE) and adverse 
events (AE) with subgroups of ocular events versus non-ocular events. Approximately 3.9% of 
subjects randomized into ranibizumab injections experienced ocular SAE (e.g. vitreous 
STUDY CER (%) EER (%) ABI (%) RBI (%) NNT (n)
RESOLVE Study 18.4 60.8 42.4 230 2.36 ! 3
2010 Diabetic Retinopathy 
Clinical Research Network 
Study
27.6 50.8 23.2 84.9 4.31 ! 5
2011 Ozturk et al* n/a n/a n/a n/a n/a
Table 2: Treatment Effects of Ranibizumab Injections in Diabetic Macular Edema Assessed by BCVA
* Data from case control study with limited results. Median BCVA improvement from 53 to 66 (p < 0.001)
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hemorrhage) versus the 0% among those in the control arm. Seventy-eight (78.4) percent of 
study participants in the ranibizumab arms experienced ocular AE (i.e. eye pain, conjunctival 
hemorrhage, and increased intraocular pressure); fifty-seven percent of those in the control arm 
experienced the same ocular AE. Non-ocular AE and SAE demonstrated similar trends with a 
likelihood of these events to occur with those receiving ranibizumab. It should be noted that the 
investigators did not attribute all reported SAE & AE to the effects of the drug  (e.g. only 60.7% 
experienced ocular AE attributed to ranibizumab by the investigators in contrast to the reported 
total 78.4 %). Additional harm effects are reported along with those of the other selected studies 
in Table 3. 
 With regard to safety in the 2010 DRCRN study, the investigators found no difference in 
the frequency of systemic, nonocular adverse events and serious adverse events; therefore only 
ocular AE & SAE are considered and examined in this review. The investigators also did not 
differentiate between an AE and SAE and, as in other studies, counted the number of events as 
opposed to the number of individuals experiencing these deleterious effects thereby altering the 
calculated RRI, ARI, and NNH. These calculated values, seen in Table 3, actually show negative 
values suggesting that ranibizumab intravitreal injections would actually reduce risk and harm to 
subjects without them. 
 Safety and adverse events were not addressed in the study conducted by Ozturk et al. 
 
STUDY CER (%) EER (%) ARI (%) RRI (%) NNH (n)
RESOLVE Study 
(Ocular SAE) 0 3.9 3.9 n/a 25.6 ! 26
RESOLVE Study 
(Ocular AE) 57.1 78.4 21.3 37.3% 4.69 ! 5
2010 Diabetic Retinopathy 
Clinical Research Network 
Study (Ocular AE & SAE)
31 21 -32.3 -10 -10
2011 Ozturk et al† n/a n/a n/a n/a n/a
Table 3: Harmful Effects of Ranibizumab Injections in Diabetic Macular Edema Assessed by AE / SAE
† Adverse events not assessed or studied in this investigation
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DISCUSSION 
 Before conclusively addressing whether or not ranibizumab is indeed effective restoring 
diminished sight in diabetics with macular edema, it is worthwhile to consider its flaws. For 
example, it should be noted that the two randomized controlled trials demonstrate the distinct 
possibility of worsening visual acuity. The RESOLVE study demonstrated that at least 7.8% 
experienced worsening visual acuity; the 2010 DRCRN study reported up to an 11% in subjects 
receiving ranibizumab and prompt focal photocoagulation. In clinical practice, these numbers 
may be high enough to warrant a great degree of caution in considering this treatment. 
 There are additional considerations to using ranibizumab as treatment for diabetic 
macular edema. During the analysis and writing of this selective review, the FDA recently 
approved its indication in the treatment of diabetic macular edema on 10 August 201210; 
therefore its novelty and projected length of time being on patent is likely to keep the price high. 
As of 2006, a 0.5 mg dose of ranibizumab (wholesale price) cost $1,950 and likely has not 
changed substantially.11 The FDA indication is for 0.3 mg per month, which would likely cost 
approximately $1,170. Although Genentech attempts to mitigate cost, it may be some time 
before health insurance companies become willing to cover any portion of these astronomical 
costs for its plan participants. 
 Ranibizumab also faces a competitor from the same manufacturer, bevacizumab (trade 
name Avastin) yet another VEGF inhibitor. Although the FDA does not approve its use in 
diabetic macular edema, studies such as the aforementioned Ozturk et al investigation have 
explored its off-label use with similar efficacy. Its cost ($17 to $50 per injection) also makes it 
substantially more appealing to prescribing practitioners.11 As it stands, ranibizumab does not 
lack challenges in its future as a therapeutic option for diabetic macular edema. 
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CONCLUSION 
 Having considered the results of these studies and limitations of the drug itself, this 
selective EBM review concludes that ranibizumab is indeed effective in improving best corrected 
visual acuity in diabetic macular edema. This monoclonal antibody is not absolutely benign nor 
is it reasonably affordable by most individuals in the United States, but since curative therapy is 
lacking, ranibizumab and similar medications may represent the promise of eventual restored 
sight and pave the way for future generations of similar therapies.  
 The future direction of research will likely involve improved and more efficient means of 
engineering and compounding the medication in a manner that reduces costs and improves its 
safety profile since monoclonal antibody therapy remains costly,13 which may prohibit patients 
and providers from accessing this effective therapeutic agent. Such research would fall under the 
purview of biomedical and biomedical engineering research to find cheaper methods of 
compounding and mass-producing ranibizumab. 
Concurrent research should expand the inclusion criteria of previous clinical research 
studies and to begin minimizing exclusion criteria to establish a clearer safety profile. Since 
patients with diabetic macular edema will likely have other comorbidities, conducting clinical 
research in these populations with other chronic pathologic processes will clarify the boundaries 
in which providers may prescribe and administer this therapy. Until such research is complete, its 
use must be carefully monitored to ensure an efficacy consistency with prior phase II & III trials 
as well as fully determine its true safety profile as it is used outside a controlled setting. 
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